Related Experiment Video

Updated: Mar 9, 2026

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
09:16

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

15.9K

Blonanserin treatment in patients with methamphetamine-induced psychosis comorbid with intellectual disabilities

Kosuke Okazaki1, Manabu Makinodan1, Kazuhiko Yamamuro1

  • 1Department of Psychiatry, Nara Medical University School of Medicine, Kashihara, Japan.

Neuropsychiatric Disease and Treatment
|December 24, 2016
PubMed
Abstract

Insights

Blonanserin effectively treated methamphetamine-induced psychosis (MAP) in patients with intellectual disabilities (ID). This antipsychotic showed good tolerability, offering a potential treatment option for this vulnerable population.

Area of Science:

  • Psychiatry
  • Pharmacology
  • Intellectual Disabilities

Background:

  • Methamphetamine (MA) use is linked to severe psychiatric issues and social impairment.
  • MA-induced psychosis (MAP) is common and treatable with antipsychotics.
  • Individuals with intellectual disabilities (ID) face increased risks from antipsychotic side effects.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of blonanserin in patients with intellectual disabilities (ID) experiencing methamphetamine-induced psychosis (MAP).

Main Methods:

  • Case study of two patients with ID and MAP.
  • Treatment involved switching to the antipsychotic blonanserin.

Main Results:

  • Blonanserin successfully improved psychotic symptoms in both cases.
  • No significant adverse effects, including sedation, were observed despite the patients' ID.

Conclusions:

  • Blonanserin shows promise as an effective and well-tolerated treatment for MAP in patients with comorbid ID.
  • Further research is needed to confirm these findings and establish blonanserin's role in this patient group.
Keywords:
blonanserinintellectual disabilitiesmethamphetaminemethamphetamine-induced psychosis

More Related Videos

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

4.8K
Development of a Virtual Reality Assessment of Everyday Living Skills10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

19.4K

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.1K
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
360
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.1K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
646
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K